Lyka Labs Ltd

Lyka Labs Ltd has experienced a marked deterioration in its valuation parameters, shifting from fair to risky territory, as reflected in its sharply negative price-to-earnings (P/E) ratio and elevated price-to-book value (P/BV). This shift underscores growing investor concerns amid subdued financial performance and sector headwinds, prompting a downgrade to a Strong Sell rating by MarketsMOJO.

Lyka Labs Ltd has seen a marked decline in its quality grading, slipping from an average to a below average rating as of 12 January 2026. This downgrade reflects deteriorating business fundamentals, including weakening profitability metrics, elevated debt levels, and inconsistent operational performance, raising concerns for investors amid a challenging market backdrop.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.71.25 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its valuation and financial metrics.

Lyka Labs Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹264.00 crores, has plunged into severe operational distress in Q2 FY26, reporting a consolidated net loss of ₹3.36 crores compared to a profit of ₹0.93 crores in the previous quarter—a staggering decline of 461.29% quarter-on-quarter. Year-on-year, the loss represents a catastrophic 260.00% deterioration from the ₹2.10 crores profit reported in Q2 FY25. The stock has responded brutally to the company's deteriorating fundamentals, collapsing 51.84% over the past year and currently trading at ₹72.57, perilously close to its 52-week low of ₹71.99.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 25 January 2026, providing investors with the latest perspective on the company’s position.

Lyka Labs Ltd’s shares declined to a fresh 52-week low of Rs.71.99 on 21 Jan 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s stock has underperformed both its sector and the broader market, reflecting a series of financial setbacks and valuation pressures.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.72.74 today, marking a significant decline amid ongoing market pressures and company-specific headwinds. The stock’s recent performance reflects a sustained downward trajectory, with notable underperformance relative to its sector and benchmark indices.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Strong Sell to Sell as of 5 January 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent financial headwinds and valuation concerns. Investors are advised to weigh the recent technical improvements against ongoing operational challenges before making decisions.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 13 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Lyka Labs Ltd’s shares touched a fresh 52-week low of Rs.73.53 today, marking a significant decline amid persistent downward momentum. The stock’s performance continues to lag behind its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology segment.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 Nov 2025. While the rating change occurred on that date, the analysis below reflects the stock’s current position as of 25 December 2025, incorporating the latest fundamentals, returns, and financial metrics.

Lyka Labs has reached a new 52-week low of Rs.73.56, marking a significant decline in its stock price amid a sustained downward trend over the past week. The pharmaceutical and biotechnology company’s shares have experienced a notable fall, reflecting ongoing pressures within its financial and operational metrics.

Lyka Labs has reached a new 52-week low of Rs.76.65, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges.

Lyka Labs has reached a new 52-week low of Rs.77.32 today, marking a significant decline amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.

Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and technical outlook. The recent changes in evaluation metrics highlight concerns across several key parameters, signalling a cautious stance from market analysts.